PRP Injections & Treatment Systems in Portland, OR

CDC PLACES vs. JF: two files, not one brochure

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 8.9% of adults in Portland have diagnosed diabetes — 3.1 points below the U.S. 12% figure. 7.1% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick prp injections against that mix.

Cash PRP and Medicare CTPs in the same hallway

• Adult arthritis here is 21.2% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 7.1% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Oregon.
• Medicare wound-care biologics in Oregon are paid under Noridian Healthcare Solutions (JF). CTP and skin-substitute LCDs are MAC-specific — a protocol that billed cleanly in another jurisdiction can stall here if documentation does not match JF coverage articles.
• Oregon Health Authority publishes state chronic-disease context that clinics can cite in patient education. Pair that with FDA 361 labeling — homologous use, minimal manipulation — so marketing does not outrun the product's actual regulatory lane.

What CDC PLACES and JF each actually tell you

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Portland is 8.9% or not. PLACES is planning data. The LCD is the claim.

Before the first prp injections shipment